{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Multiple Myeloma: An ASH 2016 Overview ((Non-Physician Credit))
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
The certificate for this activity is for NON-PHYSICIANS.Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed. While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.Purpose of Activity
To provide information on several new treatments for multiple myeloma that were presented at the American Society of Hematology meeting in 2016.Learning Objectives
After completing this continuing education activity you will be able to:
Identify the findings of several studies that examined new treatments for multiple myeloma.
Disclosures
The author, staff, and planners, including spouses/partners (if any), in any position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.
Dr. Ravi Vij has disclosed that the U.S. Food and Drug Administration has not approved the use of these drugs: daratumumab, venetoclax, selinexor, nelfinavir, BCMA CAR-T cells, GSK2857916, pembrolizumab, and carfilzomi for the treatment of multiple myeloma as discussed in this article. Please consult the product's labeling for approved information.
Price:
$10.00
Credits:
- ACCME 1.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Other Health Professional
Test Code: OTN0217
Published: Feb 2017
Expires: 1/1/2026
Sources:
Oncology Times
Required Passing Score: 7/10 (70%)
Categories:
Oncology
Specialties:
Oncology
Topics:
Multiple Myeloma